Barrow Hanley Mewhinney & Strauss LLC Has $288.82 Million Stake in Elevance Health, Inc. (NYSE:ELV)

Barrow Hanley Mewhinney & Strauss LLC cut its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 8.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 782,922 shares of the company’s stock after selling 67,718 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC’s holdings in Elevance Health were worth $288,820,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Raelipskie Partnership acquired a new position in shares of Elevance Health in the third quarter worth approximately $26,000. Flagship Wealth Advisors LLC bought a new position in Elevance Health during the 4th quarter worth approximately $26,000. Dunhill Financial LLC raised its holdings in Elevance Health by 57.8% during the 3rd quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock worth $37,000 after purchasing an additional 26 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in shares of Elevance Health in the 4th quarter worth approximately $29,000. Finally, Lee Danner & Bass Inc. bought a new stake in shares of Elevance Health in the 4th quarter valued at $30,000. Institutional investors own 89.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ELV shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $485.00 target price on shares of Elevance Health in a research note on Friday, January 24th. Stephens cut Elevance Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $520.00 to $440.00 in a research note on Wednesday, January 22nd. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Elevance Health in a research report on Friday. Argus raised shares of Elevance Health from a “hold” rating to a “buy” rating and set a $450.00 price target for the company in a research report on Monday, March 17th. Finally, Barclays raised their price objective on shares of Elevance Health from $501.00 to $512.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $519.81.

Elevance Health Trading Down 0.0 %

Shares of Elevance Health stock opened at $431.84 on Friday. The stock has a fifty day moving average price of $404.45 and a 200-day moving average price of $421.28. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. The firm has a market cap of $98.18 billion, a PE ratio of 16.86, a P/E/G ratio of 1.18 and a beta of 0.86. Elevance Health, Inc. has a 1 year low of $362.21 and a 1 year high of $567.26.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Thursday, January 23rd. The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. Equities research analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th were issued a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a yield of 1.58%. This is a positive change from Elevance Health’s previous quarterly dividend of $1.63. The ex-dividend date was Monday, March 10th. Elevance Health’s dividend payout ratio is 26.71%.

Insiders Place Their Bets

In other Elevance Health news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the sale, the executive vice president now directly owns 10,116 shares of the company’s stock, valued at $4,008,970.80. This represents a 25.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Ronald W. Penczek sold 443 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $415.13, for a total transaction of $183,902.59. Following the transaction, the chief accounting officer now owns 1,847 shares of the company’s stock, valued at $766,745.11. This represents a 19.34 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.